Needless to say, I think quite the contrary. There is plenty of...

Needless to say, I think quite the contrary. There is plenty of upside ahead, a new CEO for starters, then engagement of US manufacturing organisation to refine the kit design and collect required data for approvals. All of this with the immense benefit of hindsight, I believe they'll do well second time around, especially with $6 million to put into it!

I'm definitely in for 10 cents per share plus 20 cent options, it's a good deal. I'm seeing at least 20 - 30 cents as the year unfolds and things start moving again. Then higher with various further progress. As an investor, I also want to support their very sensible strategic plan and am not frightened by large share price fluctuations when it comes to disruptive tech. It works both ways!

There is definitely a global race to create an acceptable low cost ($50-$100) test suitable for mass population screening, the rewards for such success would be phenomenal! However I don't believe there is anything as good as Colostat so far, plus the others have already had years to come up with something, but haven't managed to.